Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.50
Ask: 46.00
Change: -0.40 (-0.89%)
Spread: 1.50 (3.371%)
Open: 44.60
High: 45.25
Low: 44.50
Prev. Close: 45.10
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Mon, 22nd Feb 2021 11:01

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Clear Leisure, up 67% at 2.09 pence, 12-month range 1.25p-2.60p. The technology sector-focused investor raises GBP1.0 million through a placing, with the cash going towards accelerating its cryptocurrency plans. Clear Leisure eyes entry into cloud mining contracts and setting up a new bitcoin mining operation in Italy.

----------

Avacta Group, up 10% at 201.40 pence, 12-month range 13.00p-224.88p. The developer of Affimer biotherapeutics and reagents notes press reports in regard to the UK government's take-up of its lateral flow SARS-CoV-2 rapid antigen test. Avacta is now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE mark for the test for professional use, aiming to bring the test to market

----------

Directa Plus, up 13% at 146.40 pence, 12-month range 46.25p-160.00p. Directa seals a supply agreement and a strategic research & development deal with Nevada, US-based lithium firm NexTech Batteries. The producer and supplier of graphene nanoplatelets based products says the supply agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement. The research & development deal also has a duration of three years and provides for joint laboratory activities, with the intention of developing new specific grades of G+ graphene nanoplatelets for a next generation of NexTech's Li-S batteries.

----------

AIM - LOSERS

----------

President Energy, down 15% at 2.07 pence, 12-month range 1.20p-3.90p. The South America-focused energy company expects to post a revenue fall of 32% to USD28 million for 2020. Says average net production in 2020 rose 12%, however.

----------

Image Scan Holdings, down 11% at 2.44 pence, 12-month range 1.00p-3.50p. The X-ray imaging firm's order intake is being hurt by Covid-19, particularly in its security segment. Image Scan says large, multi-unit orders are being delayed.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2021 19:07

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

Read more
8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

Read more
24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Read more
22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

Read more
22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Read more
18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Read more
18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

Read more
16 Feb 2021 11:31

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Read more
16 Feb 2021 09:48

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Read more
16 Feb 2021 09:38

Avacta upbeat on initial data for Covid-19 rapid test study

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.

Read more
8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

Read more
8 Feb 2021 10:46

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.